Compare PNBK & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PNBK | IMUX |
|---|---|---|
| Founded | 1999 | 2016 |
| Country | United States | United States |
| Employees | 107 | 66 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 105.9M | 100.2M |
| IPO Year | 2006 | 2013 |
| Metric | PNBK | IMUX |
|---|---|---|
| Price | $0.82 | $7.80 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $43.09 |
| AVG Volume (30 Days) | 110.3K | ★ 322.2K |
| Earning Date | 11-17-2026 | 11-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 98.31 | 38.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.80 | $0.51 |
| 52 Week High | $19.95 | $17.43 |
| Indicator | PNBK | IMUX |
|---|---|---|
| Relative Strength Index (RSI) | 43.55 | 47.20 |
| Support Level | N/A | $0.87 |
| Resistance Level | $0.91 | $8.41 |
| Average True Range (ATR) | 0.05 | 0.55 |
| MACD | 0.01 | 0.21 |
| Stochastic Oscillator | 25.41 | 70.08 |
Patriot National Bancorp Inc provides consumer and commercial banking services to individuals, small and medium-sized businesses, professionals, and municipalities in Fairfield and New Haven Counties in Connecticut and Westchester County, New York. Its products include checking accounts, savings accounts, money market accounts, time certificates of deposit, and individual retirement accounts. The Bank's lending portfolio is comprised of commercial mortgage and construction loans, commercial loans, home improvement loans, home equity lines of credit, and other personal loans. In addition, the Bank offers bank checks, money orders, automated teller machines, interactive teller machines, online and mobile banking, credit cards, and debit cards.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.